Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
Statistical analysis is the bedrock of all clinical research and drug approvals. However, this was not always the case.
Clinical trials designed using statistical principles became the norm in the US following World War II. They helped developers determine the efficacy of a drug in the broader population, but failed to consider variabilities in treatment response among individuals.
To account for those variabilities, subgroup analysis was used. Subgroup analysis was considered an extension of the traditional statistical analysis. It required teams to pre-select variables they thought would cause outcome variations then analyzed the data using mean, median, standard deviations, correlations, etc. to prove or disprove their prediction.
This type of traditional Subgroup analyses are easy to conduct and understand, however, the results can be limited. Because relying on predetermined sets of variables will not uncover novel traits that impact treatment outcomes that are not part of the original analysis plan. For example, if the team assumes that age or gender have a significant impact on outcomes, they will not discover variables related to genetics, biomarkers, or comorbidities.
Traditional statistical methods also cannot identify patterns that involve the impact of multiple variables – e.g. obese patients over the age of 50, or patients that have a specific biomarker, and failed on a prior treatment.
However, recent advances in analytics capabilities, using artificial intelligence and machine learning (AI/ML), are bringing new agility to subgroup analysis methods. With faster processing and expanded memory capacity, analysts can conduct more robust subgroup analyses, asking broader questions and relying on algorithms to uncover meaningful trends.
The most advanced platforms, including IQVIA’s Subpopulation Optimization and Modeling Solution (SOMS) solution, use algorithms to rapidly analyze broad data sets and identify traits or combinations of traits that are linked to treatment outcomes. The advanced AI/ML and augmented data visualization tools automate the analysis process, uncovering variables that bring additional precision and insight to the analysis process.
A more precise future
This ‘subgroup analysis on steroids’ brings new flexibility that wasn’t previously possible. Analysts can use it to tackle new research questions related to genomics and precision medicine, and better understand the interplay between multiple biomarkers.
These innovations do come with some new complications. Such high dimensional analysis can bring a lack of clarity and deliver results that can’t be easily explained. This risk can be mitigated by working with experts who have proficiency in using AI/ML based analysis methodologies, though such talent can be hard to find.
The lack of available skills is slowing adoption of these technologies and can affect whether regulatory agencies and providers embrace the results.
Protagonist biostatisticians and managers can address this caution by using AI/ML platforms to generate new hypotheses, then validating them using traditional statistical methods. This allows developers to leverage the power of AI/ML for cutting edge of analysis, while providing an extra layer of traditional analysis to validate the results.
As the industry becomes more familiar with this technology it will bring new power and agility to the subgroup analysis process. Eventually we will be able to determine exactly when and why patients will respond to a treatment, bringing greater safety, efficacy, and market performance for new drugs coming to market.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
Change the model of clinical research by integrating data, expertise, analytics and technology from study design through execution to power better decisions.
Improve the performance of your clinical trials with the power of the IQVIA CORE.
Getting the right outcomes from your clinical trials is all about the data and insights they provide. Biostatistics in clinical trials isn’t just a necessity, it can be a real competitive advantage.
Discover unrealized connections and manage your product across the entire lifecycle, from research and development, compliance to launch and commercialization.
Use machine learning-driven analytics to help identify promising patient subgroups, potentially preserving your investment and ensuring valuable therapies reach patients.